These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 25056116)

  • 21. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
    Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
    Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
    Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
    J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
    Wang L; Liu S; Quarles LD; Spurney RF
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does osteocytic SOST suppression mediate PTH bone anabolism?
    Kramer I; Keller H; Leupin O; Kneissel M
    Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
    Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
    Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.
    Ferrari SL; Pierroz DD; Glatt V; Goddard DS; Bianchi EN; Lin FT; Manen D; Bouxsein ML
    Endocrinology; 2005 Apr; 146(4):1854-62. PubMed ID: 15705780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats.
    Jia HB; Ma JX; Ma XL; Yu JT; Feng R; Xu LY; Wang J; Xing D; Zhu SW; Wang Y
    Osteoporos Int; 2014 Dec; 25(12):2743-54. PubMed ID: 25074352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
    Srivastava K; Tyagi AM; Khan K; Dixit M; Lahiri S; Kumar A; Changkija B; Khan MP; Nagar GK; Yadav DK; Maurya R; Singh SP; Jain GK; Wahajuddin ; Trivedi R; Chattopadhyay N; Singh D
    Phytomedicine; 2013 Apr; 20(6):470-80. PubMed ID: 23395215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Over-expression of TIMP-1 in osteoblasts increases the anabolic response to PTH.
    Merciris D; Schiltz C; Legoupil N; Marty-Morieux C; de Vernejoul MC; Geoffroy V
    Bone; 2007 Jan; 40(1):75-83. PubMed ID: 16949899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.
    Yao W; Cheng Z; Pham A; Busse C; Zimmermann EA; Ritchie RO; Lane NE
    Arthritis Rheum; 2008 Nov; 58(11):3485-97. PubMed ID: 18975341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.
    Bikle DD; Sakata T; Leary C; Elalieh H; Ginzinger D; Rosen CJ; Beamer W; Majumdar S; Halloran BP
    J Bone Miner Res; 2002 Sep; 17(9):1570-8. PubMed ID: 12211426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
    Weinstein RS; Jilka RL; Almeida M; Roberson PK; Manolagas SC
    Endocrinology; 2010 Jun; 151(6):2641-9. PubMed ID: 20410195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
    Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
    J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
    Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
    Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
    Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
    J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone.
    Knopp E; Troiano N; Bouxsein M; Sun BH; Lostritto K; Gundberg C; Dziura J; Insogna K
    Endocrinology; 2005 Apr; 146(4):1983-90. PubMed ID: 15618351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration.
    Jilka RL; Almeida M; Ambrogini E; Han L; Roberson PK; Weinstein RS; Manolagas SC
    Aging Cell; 2010 Oct; 9(5):851-67. PubMed ID: 20698835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
    Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
    J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes.
    Zanotti S; Canalis E
    Bone; 2017 Oct; 103():159-167. PubMed ID: 28676438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.
    Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY
    J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.